The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
View original at finance.yahoo.comThe Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson For Immediate Releases Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Regeneron Pharmaceuticals carries a Zacks Rank #2 (Buy)
80% confidenceMedtronic has an expected revenue and earnings growth rate of 7.5% and 2.7%, respectively, for the current year ending April 2026
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceEli Lilly has a Zacks Rank #1 (Strong Buy)
80% confidenceRegeneron Pharmaceuticals has an expected revenue and earnings growth rate of 4.9% and -0.4%, respectively, for the current year
80% confidenceJohnson & Johnson has an expected revenue growth rate of 5% for the current year
80% confidenceThe healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers
80% confidenceThe medical sector is one of the major adopters of artificial intelligence, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster as well as more accurate diagnosis
80% confidenceMedtronic has an expected earnings growth rate of 2.7% for the current year (ending April 2026)
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceEli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year
80% confidenceHypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity
80% confidenceMedtronic has an expected revenue growth rate of 7.5% for the current year (ending April 2026)
80% confidenceIntuitive Surgical has an expected revenue and earnings growth rate of 14.3% and 11.1%, respectively, for the current year
80% confidenceJNJ has an ROE of 32.7% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceRegeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year
80% confidenceMDT has an ROE of 14.9% compared with the industry's ROE of -2.5% and the S&P 500's ROE of 17%
80% confidenceEli Lilly currently sports a Zacks Rank #1 (Strong Buy)
80% confidenceRegeneron carries a Zacks Rank #2
80% confidenceRegeneron put up a decent performance in 2025 as revenues grew despite declining sales of its lead drug Eylea
80% confidenceISRG has an ROE of 15.1% compared with the industry's ROE of -18.7% and the S&P 500's ROE of 17%
80% confidenceMedtronic carries a Zacks Rank #2 (Buy)
80% confidenceJohnson & Johnson has an expected earnings growth rate of 5.7% for the current year
80% confidenceZacks top stock-picking strategies soared with average gains of +48.4%, +50.2% and +56.7% per year since 2000
80% confidenceEli Lilly has an expected earnings growth rate of 41.3% for the current year
80% confidenceThe Zacks Consensus Estimate for Eli Lilly current-year earnings has improved 0.7% over the last 30 days
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidenceREGN has an ROE of 13.8% compared with the industry's ROE of -65.41% and the S&P 500's ROE of 17%
80% confidenceZacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to S&P 500's +7.7% average gain per year
80% confidenceJohnson & Johnson carries a Zacks Rank #3 (Hold)
80% confidence